Nabsys

Executive Summary

Nabsys is a US-based genomics company that has developed the OhmX Platform, a benchtop electronic genome mapping (EGM) system designed to detect structural variants (SVs) at high resolution across the whole genome. Founded in 2004 and headquartered in Providence, Rhode Island, the company aims to make advanced SV analysis accessible and affordable for both research and clinical laboratories. Traditional short-read sequencing often misses large SVs, which are implicated in many genetic disorders and cancers. Nabsys' EGM technology directly measures DNA molecules, enabling comprehensive and unbiased detection of deletions, duplications, inversions, and translocations without amplification bias. The OhmX Platform is positioned to address the growing need for robust structural variant detection in precision medicine and molecular diagnostics. The market for genomics tools is expanding rapidly, particularly for applications in oncology, rare disease, and reproductive health. Nabsys differentiates itself through a label-free, electronic detection method that simplifies workflow and reduces cost compared to optical mapping or long-read sequencing alternatives. The company has the potential to capture significant market share if it can achieve commercial traction and establish clinical validity. Key challenges include competition from well-funded sequencing giants and the need for regulatory approvals. However, its novel approach and long development history provide a strong foundation. With a focus on partnerships and platform enhancements, Nabsys is poised to play a key role in the next wave of genomic analysis.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for OhmX Platform in Clinical Use60% success
• Q2 2026Strategic Partnership or Licensing Deal with a Major Diagnostics Company45% success
• Q3 2026Launch of Next-Generation OhmX System with Improved Throughput70% success